Moderna
MRNA
888 hedge funds and large institutions have $25.5B invested in Moderna in 2023 Q3 according to their latest regulatory filings, with 82 funds opening new positions, 353 increasing their positions, 305 reducing their positions, and 144 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 353 | Existing positions reduced: 305
12% more call options, than puts
Call options by funds: $1.71B | Put options by funds: $1.53B
0.36% less ownership
Funds ownership: 65.16% → 64.8% (-0.36%)
8% less funds holding
Funds holding: 965 → 888 (-77)
13% less funds holding in top 10
Funds holding in top 10: 15 → 13 (-2)
16% less capital invested
Capital invested by funds: $30.2B → $25.5B (-$4.75B)
43% less first-time investments, than exits
New positions opened: 82 | Existing positions closed: 144
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$189M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$107M |
| 3 |
Norges Bank
Oslo,
Norway
|
+$95.3M |
| 4 |
TP
Theleme Partners
London,
United Kingdom
|
+$72.6M |
| 5 |
Goldman Sachs
New York
|
+$70.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
-$359M |
| 2 |
LPC
Lone Pine Capital
Greenwich,
Connecticut
|
-$186M |
| 3 |
Coatue Management
New York
|
-$183M |
| 4 |
Two Sigma Investments
New York
|
-$78.3M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$69.2M |
MRNA Hedge Fund Activity: Q3 2023 in Review
888 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q3 2023, worth a combined $25.5B — down 16% from $30.2B a quarter earlier.
Sellers outnumbered buyers: 144 funds closed out of MRNA and 82 opened new positions — a net loss of 62 holders — while 305 trimmed existing stakes and 353 added.
The largest buyer was Manulife (Manufacturers Life Insurance), adding an estimated $189M. The largest seller was Flagship Pioneering, cutting an estimated $359M.
- 888 institutional investors held Moderna (MRNA) as of Q3 2023, down from 965 in Q2 2023.
- Funds reported $25.5B of Moderna stock for Q3 2023, down 16% quarter-over-quarter.
- 82 funds opened new Moderna positions in Q3 2023 and 144 closed out, a net change of -62 holders.
- The largest Moderna buyer in Q3 2023 was Manulife (Manufacturers Life Insurance), an estimated $189M added.
- The largest Moderna seller in Q3 2023 was Flagship Pioneering, an estimated $359M sold.
Based on aggregated 13F filings for Q3 2023.